Nasdaq Enta News Today

Federated Hermes Inc. acquired a new stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 133,189 shares of the biotechnology company’s stock, valued at approximately $1,253,000. Federated Hermes Inc. owned approximately 0.63% […]

Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Saturday. Separately, JPMorgan Chase & Co. decreased their target price on shares of Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” rating on the stock […]

Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday. Separately, JPMorgan Chase & Co. lowered their target price on shares of Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” […]

Clearstead Advisors LLC bought a new position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 5,064 shares of the biotechnology company’s stock, valued at approximately $57,000. Other institutional investors and hedge funds have […]

Virtus ETF Advisers LLC lowered its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) by 11.5% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 12,784 shares of the biotechnology company’s stock after selling 1,654 shares during the period. Virtus ETF Advisers LLC’s holdings in Enanta Pharmaceuticals were worth $143,000 […]

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 1,800,000 shares, a growth of 22.4% from the November 30th total of 1,470,000 shares. Approximately 9.2% of the company’s stock are short sold. […]

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report) CFO Paul J. Mellett sold 2,412 shares of the firm’s stock in a transaction dated Tuesday, December 5th. The stock was sold at an average price of $9.63, for a total value of $23,227.56. Following the sale, the chief financial officer now directly owns 93,549 shares in […]

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report) VP Brendan Luu sold 2,125 shares of the stock in a transaction that occurred on Tuesday, December 5th. The stock was sold at an average price of $9.63, for a total value of $20,463.75. Following the sale, the vice president now directly owns 36,736 shares in the […]

Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) had its price objective lowered by HC Wainwright from $30.00 to $28.00 in a report issued on Tuesday, Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock. A number of other analysts have also weighed in on ENTA. JPMorgan Chase & Co. lowered shares […]

Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) had its price target trimmed by JMP Securities from $42.00 to $23.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has an outperform rating on the biotechnology company’s stock. Other research analysts have also recently issued reports about the company. Jefferies Financial Group […]